Results 131 to 140 of about 17,680 (157)

Association between PD1 mRNA and response to anti-PD1 monotherapy across multiple cancer types [PDF]

Annals of Oncology, 2018
We hypothesized that the abundance of PD1 mRNA in tumor samples might explain the differences in overall response rates (ORR) observed following anti-PD1 monotherapy across cancer types.
Elísabeth Pérez Ruiz, Tomás Pascual, Miguel A Molina-Vila   +2 more
exaly   +3 more sources

Some of the next articles are maybe not open access.

Related searches:

PKCα/ZFP64/CSF1 axis resets the tumor microenvironment and fuels anti-PD1 resistance in hepatocellular carcinoma

Journal of Hepatology, 2022
Jian Gao, Jia Fan, Chao Gao
exaly  

Bispecific Aptamer-Based Recognition-then-Conjugation Strategy for PD1/PDL1 Axis Blockade and Enhanced Immunotherapy

ACS Nano, 2022
Liping Qiu, Xiaohong Fang, Yu Yang
exaly